ArticleNews reportPHN-04922026-10-30 21:07 CT

Citigroup raises Eli Lilly target to $1600

Source · scanx.trade

TLDR

ScanX reports that Citigroup analyst Geoff Meacham raised Eli Lilly’s stock price target to $1,600 from $1,500 while maintaining a Buy rating. Several other firms also raised their targets, but the main article provides no peptide-specific clinical or regulatory developments.

01—Key points

01UBS, Bernstein, B of A Securities and Truist also increased their price targets.
02The article describes Guggenheim’s revision as a reduction, although its listed figures show an increase from $1,235 to $1,273.
03A separate appended article reports Lilly Canada’s announcement of pediatric approval for Mounjaro (tirzepatide).

Why it matters Editorial

The main report concerns analyst expectations for Lilly’s stock rather than evidence about peptide treatments.

Read the original at scanx.trade↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.